Stock Financial Ratios, Dividends, Split History

TACO / Del Taco Restaurants, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)539.88
Enterprise Value ($M)706.69
Book Value ($M)420.16
Book Value / Share10.93
Price / Book1.30
NCAV ($M)-303.46
NCAV / Share-7.89
Price / NCAV-1.80
Share Statistics
Common Shares Outstanding 38,445,409
Scoring Models
Piotroski F-Score1.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)n/a
Return on Assets (ROA)n/a
Return on Equity (ROE)n/a
Balance Sheet (mrq) ($M)
Quick Ratio0.33
Current Ratio0.39
Income Statement (mra) ($M)
Franchise Revenue0.00
Sales Revenue Net0.00
Reimbursement Revenue0.00
Cash Flow Statement (mra) ($M)
Identifiers and Descriptors
Central Index Key (CIK)1585583

Split History

Stock splits are used by Del Taco Restaurants, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

Stocks To Watch: Don't Sleep On Vienna

2018-06-16 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. (526-2)

Why Wedbush Is Betting Big on Del Taco

2018-06-13 247wallst
Del Taco Restaurants, Inc. (NASDAQ: TACO) shares saw a slight bump on Wednesday after one key analyst upped its price target on the taco chain. The upshot from this report is tasty returns for investors. (2-0)

Groups That Are Leading Nasdaq Higher - Cramer's Mad Money (6/4/18)

2018-06-05 seekingalpha
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Monday, June 4. (359-1)

Marriott (MAR) Stock Up 35% in a Year: Can it Gain Further?

2018-05-11 zacks
Marriott International, Inc. (MAR - Free Report) is riding high on Starwood acquisition, improving North-American business, strong RevPAR gains, sizeable international exposure, an attractive brand-position and positive earnings streak. In a year’s time, the stock has rallied 35.3%, outperforming the industry’s gain of 24.7%. However, lingering political uncertainties in key international markets and currency headwinds might persistently limit revenue growth. (7-0)

YUM! Brands (YUM) Stock Up 22% in a Year: More Room to Run?

2018-05-10 zacks
YUM! Brands, Inc. (YUM - Free Report) looks promising on the back of its effort to drive growth by developing its three iconic global brands and creating a more efficient cost structure. In the past year, shares of the company have rallied 22.2%, outperforming the industry’s increase of 4.8%. However, the stock recently came under pressure after the company’s comps growth came in below the analyst expectations. (12-0)

CUSIP: 245496104